From: Adjuvant therapy of melanoma with interferon: lessons of the past decade
References Intergroup Trial | AJCC Stage | # Total Patients enrolled | Arms | # Patients for arm | RFS P value | OS P value |
---|---|---|---|---|---|---|
Creagan et al. (1995)54 NCCTG 83–7052 | II–III | 262 | 2 | HDI 131 Control 131 | 0.19 | 0.40 |
Kirkwood et al. (1996)1 ECOG E1684 | IIB–III | 287 | 2 | HDI 143 Control 137 | 0.0023 | 0.0237 |
Grob et al. (1998)34 French CGM | IIAB | 499 | 2 | LDI 253 Control 246 | 0.035 | 0.059 |
Pehamberger et al.(1998)58 Austrian MMCG | IIAB | 311 | 2 | LDI 154 Control 157 | 0.02 | n.d |
Kirkwood et al. (2000)25 ECOG-US Intergroup E1690 | IIB–III | 642 | 3 | HDI 203 LDI 203 Control 202 | 0.03* 0.17** | 0.744* 0.672** |
Kirkwood et al. (2001)26 ECOG-US Intergroup E1694 | IIB–III | 774 | 2 | HDI 385 GM2/QS-21 389 | 0.006 | 0.04 |
Cascinelli et al. (2001)59 WHO 16 | III | 444 | 2 | LDI 218 Control 208 | 0.50 | 0.72 |
Cameron et al. (2001)60 Scottish MG | II–III | 96 | 2 | LDI 47 Control 49 | > 0.1 | > 0.2 |
Hancock et al. (2004)61 UKCCCR-MCG | IIB–III | 654 | 2 | LDI 338 Control 336 | 0.3 | 0.6 |
Kleeberg et al. (2004)62 EORTC 18871 | II–III | 423 | 3 | UDI 240 IFNγ 244 Control 244 | 0.71° 0.73°° | 0.72° 0.25°° |
Kleeberg et al. (2004)62 DKG-80 | II–III | 407 | 4 | Iscador 102 Control 102 | 0.12 | 0.31 |
Eggermont et al. (2005)31 EORTC 18952 | IIB–III | 1418 | 3 | HID-IFN 565 LID-IFN 569 Control 284 | 0.1* | 0.2* |
Eggermont et al. (2008)32 EORTC 18991 | III | 1256 | 2 | PEG-IFN 627 Control 629 | 0.011# 0.107## | 0.78 |
Gogas et al. (2007)33 He.Co.G | IIBC–III | 364 | 2 | HDI 1 mos 182 HDI 12 mos 182 | 0.94 | 0.51 |